Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Shionogi & Co ( (JP:4507) ) has issued an announcement.
Shionogi & Co. announced positive results from a Phase 2 trial of its RSV oral antiviral candidate S-337395, which showed a significant reduction in viral load and was well-tolerated with no serious adverse events. The drug, which inhibits the L protein essential for virus replication, has received Fast Track designation from the FDA due to the unmet need for effective RSV treatments, particularly for vulnerable populations such as infants and older adults.
More about Shionogi & Co
Shionogi & Co., Ltd. is a pharmaceutical company based in Osaka, Japan, with a focus on developing treatments for infectious diseases. The company is committed to protecting people worldwide from infectious disease threats and is expanding its portfolio to include treatments for acute respiratory infections such as influenza, COVID-19, and RSV. Shionogi is collaborating with UBE Corporation, which specializes in specialty chemicals and pharmaceuticals, to advance the development of novel therapeutics.
YTD Price Performance: 20.32%
Average Trading Volume: 531
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $13.36B
Learn more about 4507 stock on TipRanks’ Stock Analysis page.
